Medscape8d
Post-COVID Cough Linked to Neurologic Dysfunction
Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.
pharmaphorum3d
FDA stifles Merck's cough drug gefapixant, asking for more data
It is slightly ahead of Bellus Health with BLU-5937, another P2X3 inhibitor ... for patients with refractory or unexplained chronic cough and will work with the FDA to address the agency's ...
pharmaphorum2d
Bayer's eliapixant hits the right notes in PAGANINI cough study
Both drugs are selective P2X3 receptor antagonists, designed to inhibit a hypersensitisation of the cough reflex in people struggling with chronic cough. At the moment there are no approved ...